Workshop Purpose

Workshop Main Page  |  Highlights  |  Program Purpose  |  Presentations Slides & Schedule | Faculty
Preliminary Program  |  Photos

October 1, 2010
Hyatt Regency Washington on Capitol Hill
Washington, D.C.

Program Purpose

Intended Audience
The primary audience for the 2010 workshop includes scientist and clinicians from regulatory agencies, industry, and academics who are interested in understanding more about monoclonal antibodies (mAbs). The Workshop will facilitate interactive discussion on mechanisms of action responsible for clinical efficacy of monoclonal antibodies, mechanisms of resistance to monoclonal antibodies and how to best utilize current knowledge to develop more effective antibody-based cancer treatments.

Program Goals

• Critically evaluate the strategies for understanding mAb mechanisms of action.
• Assess the leading target antigens for most tumor types.
• Examine the potential to modify the IgG structure and to produce a more effective mAb.
• Identify the most promising immunologic targets and desired changes for immunomodulatory antibodies.
• Discuss the advantages and disadvantages of using mAbs as vaccines relative to recombinant antigen and other vaccine approaches.

Expected Learner Outcomes
Upon completion of this meeting, participants will be able to:

• Discuss the strategies for understanding mAb mechanisms of action.
• Define the leading target antigens for most tumor types.
• Describe the potential to modify the IgG structure and to produce a more effective mAb.
• Understand the most promising immunologic targets and desired changes for immunomodulatory antibodies.
• Summarize the advantages and disadvantages of using mAbs as vaccines relative to recombinant antigen and other vaccine approaches.

The Workshop on Monoclonal Antibodies in Cancer is a non-accredited continuing medical education event. No credits are offered for physician participation in this educational program.